Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$2.25
Day's Change
-0.2236 (-9.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.31
Day's Low
2.16
Volume
(Heavy Day)

Today's volume of 168,474 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.

168,474

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Enviva Inc. (EVA) Investors of Class Action and Last Few Hours to Actively Participate

2:48 pm ET January 3, 2023 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / January 3, 2023 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Enviva Inc.("Enviva" or the "Company") (NYSE:EVA) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquiredEnviva securities between February 21, 2019 and October 11, 2022, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/eva.

Bronstein, Gewirtz and Grossman, LLC, Tuesday, January 3, 2023, Press release picture

This class action seeks to recover damages against Defendants for alleged violations of the Securities Exchange Act of 1934 (the "Exchange Act").

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had misrepresented the environmental sustainability of its wood pellet production and procurement; (2) the Company had similarly overstated the true measure of cash flow generated by the Company's platform; (3) accordingly, the Company had misrepresented its business model and the Company's ability to achieve the level of growth that Defendants had represented to investors; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/eva or contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Enviva,you have until January 3, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC





View source version on accesswire.com:

https://www.accesswire.com/733867/Final-Deadline-Alert-Bronstein-Gewirtz-Grossman-LLC-A-Successful-Firm-Reminds-Enviva-Inc-EVA-Investors-of-Class-Action-and-Last-Few-Hours-to-Actively-Participate



comtex tracking

COMTEX_421834562/2457/2023-01-03T14:48:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.